Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...

Why doesn't CAR-T cell therapy provide a lasting benefit for more patients with DLBCL? Cleveland Clinic's Brian Hill, MD, PhD delves into the issues. (2:51) Share on Facebook. Opens in a new tab ...

Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor, SLS009, in treating relapsed/refractory diffuse large B ...

Opens in a new tab or window Why doesn't CAR-T cell therapy provide a lasting benefit for more patients with DLBCL? Cleveland Clinic's Brian Hill, MD, PhD delves into the issues. (2:51 ...

The mutation burden in DLBCL varies significantly based on patient sex and age, according to recent findings published in ...

Much of MorphoSys’ portfolio – including marketed diffuse large B-cell lymphoma (DLBCL) therapy Monjuvi (tafasitamab), partnered with Incyte – is licensed to other companies. The news has ...

The trial included 230 patients who received at least two previous lines of systemic therapy, were considered ... landscape for relapsed or refractory DLBCL given the availability of other ...

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD ...